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Background: Emergence agitation after sevoflurane anesthesia in children can be prevented by midazolam. 
Alternative splicing of the GABAA receptor changes with age. Therefore, we hypothesized that alternative splicing of 
the γ2 subunit affects the GABA current when applying sevoflurane and midazolam.
Methods: We performed the whole­cell patch clamp technique on human embryonic kidney 293 cells that were 
transfected with α1β2γ2L or α1β2γ2S. The concentration­response relations were recorded for midazolam and 
sevoflurane, and the co­application responses were measured at concentrations of 1.5 nM, 15 nM and 300 nM of 
midazolam and 0.5%, 2.0% and 4.0% of sevoflurane. Each GABA current was compared with that produced by 5 μM 
of GABA.
Results: The concentration­response relationships for midazolam and sevoflurane were dose­dependent without 
any differences between the α1β2γ2L and α1β2γ2S subtypes. 1.5 nM and 15 nM of midazolam did not significantly 
enhance the current after treatment with 0.5% sevoflurane for both subtypes. The current after treatment with 2.0% 
sevoflurane was enhanced by 1.5 nM midazolam for the α1β2γ2S subtype, but not for the α1β2γ2L subtype. In the 
case of 2.0% sevoflurane with 15 nM of midazolam, and 4.0% sevoflurane with 300 nM of midazolam, the GABA 
currents were significantly enhanced for both subtypes.
Conclusions: These results show that the difference in the γ2 subunit cannot explain the emergence agitation after 
sevoflurane anesthesia in children in vitro. This suggests that co­application of sevoflurane and midazolam enhances 
the GABA current according to the alternative splicing of the γ2 subunit and the concentration of both drugs. (Korean 
J Anesthesiol 2011; 60: 109­118)
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Introduction
    The GABAA receptor mediates rapid inhibitory action by 
using GABA, which is a major inhibitory neurotransmitter of 
the central nervous system. Activation of the GABAA receptor 
induces the opening of chloride channels and this increases 
the inward chloride current. The hyperpolarization of the 
membrane of neurons then decreases the post­synaptic action 
potential of the neuron [1]. 
    As the GABAA receptor has specific binding sites for GABA, 
barbiturate, benzodiazepines and the anesthetic steroids, which 
induces sedation, hypnosis, amnesia or anesthesia through 
their binding, the GABAA receptor is considered to be a major 
target protein of anesthesia [2]. 
    The GABAA receptor is a complex of 5 subunits of 19 different 
subunits (α, β, γ, δ, ε, π, θ, ρ, etc.) in mammals. Multiple 
combinations from the different subunits make several subtypes 
of GABAA receptor. Most GABAA receptors consist of two α 
subunits, two β subunits and a γ subunit. The complexity of 
GABAA receptors is still under investigation and there exits the 
possibility of new combinations of subunits. Each combination 
of different subunits has unique physiologic characteristics and 
the drug responses are different from each other [3]. 
    The γ2 subunits of the GABAA receptor exist as a long type 
(γ2L) and a short type (γ2S) by alternative splicing of RNA. The 
γ2L subunits have another 8 amino acids (LLRMFSFK) in the 
intracellular loop and the phosphorylation by protein kinase C 
(PKC) occurs in this region (Ser343) [4]. 
    It seems that the agents binding to the γ2 subunit may have 
different effects according to the subtype. The total expression 
of the γ2 subunit is similar for all ages, but γ2L/γ2S increases 
by the up­regulation of the γ2L subunit and γ2L becomes 
dominant in mature synapses according to age [5,6]. 
    The distribution and pattern of GABAA receptors are various 
according to the region of the central nervous system and the 
type of neuron. This is also true for γ2L and γ2S [7,8]. The most 
common pattern of GABAA receptor is the α1β2γ2 type, which is 
43% of all the GABAA receptors [9]. This implies that the diversity 
of the subtype variants and the distribution of GABAA receptors 
may affect the effect of anesthetics and induce different effects 
from subject to subject.
    Midazolam is a popular sedative and sevoflurane is a most 
commonly used inhalational anesthetic. It is known that these 
drugs show their sedative, hypnotic or anesthetic actions 
by binding to GABAA receptors. The GABAA receptor has the 
loci for binding to benzodiazepine, barbiturate and steroids. 
Midazolam activates the GABAA receptor by augmenting 
the binding of GABA to the receptor and midazolam directly 
activates the GABAA receptor at a high concentration. The γ2 
subunit is essential for binding benzodiazepine to the GABAA 
receptor [10]. 
    Sevoflurane is a volatile anesthetic that was developed 
relatively recently, and it is now widely used and preferred for 
clinical anesthesia, and especially for pediatric anesthesia. 
Sevoflurane has been reported to potentiate GABA­induced 
currents at the GABAA receptor. Sevoflurane enables the rapid 
induction and quick recovery after inhalational anesthesia 
when using it because sevoflurane possesses several favorable 
properties, including low blood and tissue solubility, non­
pungency and limited cardiorespiratory depression, which may 
make sevoflurane desirable for use in infants and children [11]. 
The quick recovery from sevoflurane is likely to be accompanied 
by emergence agitation, which often occurs after administering 
sevoflurane in children even when sufficient analgesia is 
provided [12,13]. 
    One of the trials to reduce the unpleasant effects during 
emergence is to use midazolam as premedication. It has been 
reported that premedication with oral midazolam is effective 
for decreasing the occurrence of emergence agitation without 
delaying the discharge from the post­anesthesia care unit and 
so this is safe and suitable for outpatient surgery [14]. However, 
the mechanism is still not clear, and it is not known whether 
sevoflurane and midazolam have the interaction at the level of 
the GABAA receptor. 
    The mechanism of agitation was described in the model of 
Sachdev and Kruk as the result of decreased inhibitory signals 
to the globus pallidus interna/substantia nigra pars or the 
disinhibition of the thalamocortical neurons and brain stem 
neurons by the disturbance of neuronal circuits [15]. So, it is 
expected that the change of GABAA receptor activity may cause 
or reduce emergence agitation. 
    We postulated that alternative splicing of γ2 subunit is related 
with the occurrence of emergence agitation on the basis of the 
characteristics of midazolam, sevoflurane and the γ2 subunit; 
sevoflurane binds to GABAA receptor, a benzodiazepine like 
midazolam prevents emergence agitation and binds to the α 
and γ subunits of the GABAA receptor, and alternative splicing 
of the γ2 subunit is different according to age. Therefore, 
we performed the whole­cell patch clamp to the α1β2γ2L 
and α1β2γ2S GABAA receptors that are expressed on human 
embryonic kidney (HEK) 293 cells with using midazolam and/
or sevoflurane.
Materials and Methods
Transfection of the γ2 cDNA of the GABAA receptor to 
the HEK cells
    HEK 293 cells are suitable for the transient expression of 
GABAA receptors and electrophysiological study [16]. Culturing 111 www.ekja.org
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of the HEK 293 cells and expressing GABAA cDNA in the HEK 
293 cells were performed as previously described [17].
    The HEK 293 cells (CRL­1573; American Type Culture 
Collection) were cultured on glass cover slips in a solution 
containing minimum essential medium (MEM) supplemented 
with 10% heated fetal bovine serum, glutamine (4 mM), 
penicillin G (100 U/ml) and streptomycin sulfate (100 μg/ml). 
    Human γ2S cDNA was made from human γ2L cDNA (JC 
Biotech, Seoul, Korea) by deletion mutagenesis and its 
sequence was confirmed by polymerase chain reaction.
    The γ­aminobutyric acid type A receptor complementary 
DNAs (the human γ2L or γ2S cDNA, the rat α1 cDNAs and the 
rat β2 cDNAs: the rat α1 and β2 cDNAs were generous gifts from 
Dr. Werner Sieghart, Professor of Biochemistry and Molecular 
Pharmacology, and Head of the Department of Biochemistry 
and Molecular Biology, Center for Brain Research, Medical 
University Vienna, Vienna, Austria) were expressed in the 
human embryonic kidney (HEK) 293 cells along with the 
cDNA of green fluorescent protein as previously described. 
For the transient expression of GABAA receptors, the cells 
were transfected using the CaPO4 precipitation technique as 
previously described [18].
    The GABAA receptor cDNAs and green fluorescent protein 
cDNA were precipitated for 60 min at room temperature in 65 
μl of distilled water that contained 8 μl of 2.5 M CaCl2, 750 μl 
of 50 mM N, N­bis [2­hydroxyethyl]­2­aminoethanesulfonic 
acid and 5 μg of each cDNA. The mixture was added to the cells 
grown on the cover slips. The cDNA was in contact with the 
HEK cells for 24 h in an atmosphere containing 3% CO2 (37
oC) 
before being removed and replaced with fresh culture medium 
in an atmosphere of 5% CO2 (37
oC). The transfected cells were 
cultured on cover slips for 48-72 h after cDNA removal. The 
cover slips were transferred to a 35 mm culture dish 1 h before 
the whole­cell patch clamp. 
Electrophysiological recording
    A cover slip was mounted on the recording chamber and it 
was continuously perfused with extracellular solution (145 mM 
NaCl, 3 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2, 6 mM D­glucose 
and 10 mM HEPES/NaOH adjusted to pH 7.4) at a rate of 10 ml/
min.
    The whole cell patch clamp recordings from the fluorescing 
HEK 293 cells (voltage clamped at -60 mV) were made using a 
EPC 10 USB amplifier (HEKA Electronik, Lambrecht, Germany) 
under a fluorescence microscope (Olympus IX71; Olympus Co. 
Ltd., Tokyo, Japan) at room temperature (22
oC) as described 
previously.
    The patch pipette was made by using a PC­10 puller (Narishige 
Co., Tokyo, Japan) and a glass capillary tube (outer diameter: 
1.5 mm, Harvard Apparatus Ltd., Edenbridge, Kent, UK). The 
resistance of the patch pipette was 4-6 M when it was filled 
with intracellular solution (145 mM N­methyl­D­glucamine 
HCl, 5 mM HEPES/KOH and 0.1 mM CaCl2, pH 7.2). 
    The expression of GABA cDNA was confirmed by the develop­
ment of intrinsic current, which was measured from the 
fluorescing HEK 293 cells, but not from the non­fluorescing 
cells by the application of GABA (10 μM) and inhibition of the 
intrinsic current by the application of bicuculline (10 μM), 
which is an antagonist of the GABAA receptor. 
    In addition to the continuous bath perfusion with extracellular 
solution, solutions including GABA, sevoflurane or midazolam 
were applied to the cells for 3 s at a rate of 10 ml/min using a 
manual valve controller. The solutions were rinsed away for at 
least 1 min to minimize the residual effect of other solutions. 
    Stock solutions of GABA and midazolam (Midacom
Ⓡ, Myung­
moon Pharm., Korea) were diluted in the extracellular solutions 
shortly before use. The sevoflurane (Sevorane
Ⓡ, Abbott Korea, 
Korea) solutions were prepared by a sevoflurane vaporizer 
(Vapor 2000
Ⓡ, Draeger Medical, Germany). The extracellular 
medium was bubbled with a vaporized sevoflurane and oxygen 
mixture. The concentration of sevoflurane was measured by an 
anesthetic gas monitor (Vamos
Ⓡ, Draeger Medical, Germany). 
The agents without specific notification were purchased from 
Sigma (St. Louis, MO, USA). 
Response of the GABAA receptors to GABA 
    The concentration­response curve of GABA was obtained 
by applying 6 different concentrations of GABA solutions in 
a row (0.1-1,000 μM) to the GABAA receptors for 3s after the 
cells were superfused with extracellular medium, followed 
by a return to extracellular medium for at least 1 min before 
any subsequent GABA application. As the currents for 5 μM of 
GABA were similar to 20% of the maximum response in both 
subtypes, 5 μM of GABA was used for comparison of each of the 
currents made by the midazolam and/or sevoflurane. 
Response of the GABAA receptors to midazolam and 
sevoflurane
    The current for 5 μM of GABA was measured as a control 
current for each cell before the application of sevoflurane and/
or midazolam. The current for each drug was divided by the 
control current, and the ratio was used for comparison. 
    The concentration­response curves of midazolam and 
sevoflurane were obtained by the application of 4 different 
concentrations of midazolam (15-10,000 nM) or sevoflurane 
(0.5-8.0%) in a row for 3 s together with 5 μM of GABA for 
both subtypes and the 3 sets of concentrations of those were 112 www.ekja.org
GABA receptor, midazolam and sevoflurane Vol. 60, No. 2, February 2011
obtained for comparison. To determine the interaction of 
midazolam and sevoflurane, midazolam and sevoflurane were 
cross­applied together with 5 μM of GABA at the concentration 
of 1.5 nM (minimum response), 15 nM and 300 nM (maximum 
response) of midazolam and at the concentration of 0.5%, 2.0% 
(1 MAC) and 4% (2 MAC) of sevoflurane for both subtypes. 
Statistical analysis
    Origin 6.1 (MicroCal, Northampton, USA) and Microsoft Excel 
2007 (Microsoft, Redmond, USA) were used for the statistical 
analysis. All the data is expressed as means ± standard errors. 
The measured currents of each agent were converted to the ratio 
of the measured current of each agent to the current measured 
by GABA 5 μM. Student's t­test was used for comparing the 
differences of each ratio. P values < 0.05 were considered 
statistically significant.
Results
Confirming the expression of GABAA receptor on the 
HEK 293 cells
    There were no current changes according to GABA (10 μM) 
or no fluorescences in the non­transfected cells (Fig. 1). Yet 
the transfected cells showed green fluorescences and inward 
current due to GABA (10 μM) for both subunits (Fig. 1). 
Application of bicuculline (10 μM) decreased the current by 
10.3 ± 4.5% for the α1β2γ2L subtype (n = 13) and by 7.5 ± 3.2% 
for the α1β2γ2S subtype (n = 6) (Fig. 2). The responses to GABA 
were recovered by the superfusion of extracellular solution for 
3 min. This means that α1β2γ2L cDNA or α1β2γ2S cDNA was 
successfully transfected to the HEK 293 cells. 
Response to GABA at the α1β2γ2L and α1β2γ2S GABAA 
receptor
    The responses to GABA increased in a concentration­
dependent manner for both the α1β2γ2L and α1β2γ2S subtypes. 
The EC50 of the α1β2γ2L subtype was 37.2 μM (n=53) (Fig. 3) and 
the EC50 of the α1β2γ2S subtype was 17.1 μM (n = 66) (Fig. 4). 
Fig. 1. The HEK 293 cells with α1β2γ2L and α1β2γ2S GABAA receptors. 
The HEK293 cell without fluorescence shows no inward current. The 
inward currents are reduced after the application of bicuculline (10 
μM) and they reappear after washout of bicuculline.
Fig. 2. Reduction of the GABAA receptor response after the application of bicuculline (10 μM). This reduction is reversed after washout of 
bicuculline. *P value < 0.05, when compared to the currents by GABA (10 μM).113 www.ekja.org
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The maximum responses were 3.7 ± 0.4 nA for the α1β2γ2L 
subtype and 3.1 ± 0.6 nA for the α1β2γ2S subtype without a 
statistically significant difference. The EC20 was 4.5 μM and 4.1 
μM for α1β2γ2L and α1β2γ2S, respectively.
Response to midazolam and sevoflurane at the 
α1β2γ2L and α1β2γ2S GABAA receptors
    Midazolam increased the current in response to GABA (5 
μM) for both subtypes, and this was dependent on the increase 
of its concentration (Fig. 5 and 6). There were no differences 
of the EC50 of midazolam (249 nM for the α1β2γ2L subtype (n 
= 37) and 211 nM for the α1β2γ2S subtype (n = 34)) or for the 
maximum responses (303 ± 35% for the α1β2γ2L subtype and 
329 ± 33% for the α1β2γ2S subtype).
    The response to GABA (5 μM) was increased depending on 
the concentration of sevoflurane for both subtypes (Fig. 7 and 
8). The EC50 of sevoflurane was 4.8% for the α1β2γ2L subtype 
(n = 20) and 5.2% for the α1β2γ2S subtype (n = 15), and the 
maximum response was 368 ± 87% and 412 ± 103% for both 
types, respectively. The difference was not significant. This 
means there were no differences according to the subtypes for 
midazolam and sevoflurane.
Fig. 3.  Dose-response curve to GABA for α1β2γ2L GABAA receptor. 
The response is concentration-dependent. The data is expressed 
as means ± SEMs (6, 6, 13, 16, 8 and 4 cells were used at the 
concentrations of 1, 3, 5, 10, 50 and 200 μM, respectively).
Fig. 4. Dose-response curve to GABA for α1β2γ2S GABAA receptor. 
The response is concentration-dependent. The data is expressed 
as means ± SEMs (8, 9, 18, 17, 11 and 3 cells were used at the 
concentration of 1, 3, 5, 10, 50 and 200 μM, respectively). *P value < 
0.05, when compared with the γ2L form.
Cross-response of midazolam and sevoflurane at the 
α1β2γ2L and α1β2γ2S GABAA receptors 
    We measured the cross­responses of 1.5 nM and 15 nM of 
midazolam and 0.5% and 2.0% of sevoflurane. The response of 
300 nM of midazolam to 4.0% of sevoflurane was also measured.
    There was no effect of 1.5 nM of midazolam to 0.5% of 
sevoflurane for both the α1β2γ2L subtype (n = 4) and the α1β2γ2S 
subtype (n = 4). The ratio of the current to the control current was 
136% and 135%, respectively (Fig. 9A). 15 nM of midazolam did 
not affect the response of 0.5% of sevoflurane either (n = 5 and 
3). The ratio of the current to the control current was 194% and 
200%, respectively (Fig. 9B). There was a significant difference 
for the co­application of 1.5 nM of midazolam and 2.0% of 
sevoflurane (Fig. 10A). Midazolam increased the response of 
sevoflurane for the α1β2γ2S subtype (n = 4), but not for the 
α1β2γ2L subtype (n = 6). The ratio was 227% to 154%. There was 
significant increases of the response to 2.0% of sevoflurane and 
15 nM of midazolam for both subtypes without any differences 
between the α1β2γ2L subtype (n = 6, 225%) and the α1β2γ2S 
subtype (n = 3, 258%) (Fig. 10B). 
    The response of 300 nM of midazolam and 4.0% of sevoflurane 
showed significant increases of the GABA current in the cells 114 www.ekja.org
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with both the α1β2γ2L subtype (n = 4, 369%) and the α1β2γ2S 
subtype (n = 4, 355%) but there was no significant difference 
between the two subtypes (Fig. 11). 
    This means that 1.5 nM of midazolam inhibited the GABA 
current according to 2.0% of sevoflurane by affecting the 
phosphorylation of protein kinase C in the α1β2γ2L subtype.
Discussion
    The purpose of this study is to determine the difference of the 
GABA currents by the interaction of sevoflurane and midazolam 
at the GABAA receptor with the γ2L or γ2S subunit and whether 
the currents according to sevoflurane and/or midazolam are 
influenced by the difference of the γ2 subunit. The results 
showed that the GABA currents according to sevoflurane could 
be partially modulated by midazolam.
    The induction of general anesthesia for children has greatly 
improved since sevoflurane was introduced. Sevoflurane 
enabled easy, smooth and rapid inhalational anesthesia for 
children because it can be inhaled at the high concentration 
with a non­pungent odor and there is less irritability of the 
airway even in an awake condition.
    Emergence agitation is described that the patients are 
irrationally excited, agitated, restless, combative, frightened 
and non­cognizant, and the patients refuse parental care. 
Sometimes these patients have needed physical restraints [19]. 
This agitation is usually a self­limiting condition that subsides 
in an hour without any sequels or memory, but this makes 
the care of the patient difficult in the post­anesthesia recovery 
room. The physical over activity can be harmful to the patients 
and additional medical intervention with sedatives can prolong 
the stay in the post­anesthesia care unit [20]. The mechanism 
of this phenomenon has not been clearly explained, but there 
have been several theories and one of them is the change of 
activity of the GABAA channels in the central nervous system 
[15]. Clinical trials have been performed to alleviate this activity 
such as premedication with sedatives and regional anesthesia. 
Among them, premedication with a benzodiazepine like 
midazolam has been reported to be safe and useful [14]. 
Midazolam has the effects of amnesia, unconsciousness and 
anxiolysis, it has a broad therapeutic range and it causes less 
depression of the cardiovascular system. Its properties have 
Fig. 6. Midazolam’s potentiation of the GABA (5 μM)-evoked 
response for the α1β2γ2S GABAA receptor. The responses evoked 
by 5 μM GABA are potentiated by increasing concentrations of 
midazolam (13, 8, 6 and 7 cells were used at the concentration of 1.5, 
15, 300 and 1,500 nM, respectively).
Fig. 5. Midazolam’s potentiation of the GABA (5 μM)-evoked 
response for the α1β2γ2L GABAA receptor. The responses evoked 
by 5 μM GABA are potentiated by increasing concentrations of 
midazolam (15, 7, 8 and 7 cells were used at the concentration of 1.5, 
15, 300 and 1,500 nM respectively).115 www.ekja.org
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Fig. 7. Sevoflurane’s potentiation of the GABA (5 μM)-evoked 
response for the α1β2γ2L GABAA receptor. The responses evoked 
by 5 μM GABA are potentiated by increasing concentrations of 
sevoflurane (4, 4, 4 and 8 cells were used at the concentration of 0.5, 2, 
4 and 8%, respectively).
Fig. 8. Sevoflurane’s potentiation of the GABA (5 μM)-evoked 
response for the α1β2γ2S GABAA receptor. The responses evoked 
by 5 μM GABA are potentiated by increasing concentrations of 
sevoflurane (3, 4, 2 and 6 cells were used at the concentration of 0.5, 2, 
4 and 8%, respectively).
Fig. 9. (A) Sevoflurane (0.5%) enhancement of the currents evoked by co-application of midazolam (1.5 nM) and GABA (5 μM) for the α1β2γ22L 
and α1β2γ2S GABAA receptors. MDZ: midazolam, Sevo: sevoflurane. The data is expressed as means ± SEMs (4 cells for γ2L and 4 cells for γ2S 
were used.). (B) Sevoflurane (0.5%) enhancement of the currents evoked by the co-application of midazolam (15 nM) and GABA (5 μM) at the 
α1β2γ2L and α1β2γ2S GABAA receptors. MDZ: midazolam, Sevo: sevoflurane. The data is expressed as means ± SEMs (4 cells for γ2L and 3 cells 
for γ2S were used).116 www.ekja.org
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Fig. 10. (A) Sevoflurane (2.0%) enhancement of the currents evoked by the co-application of midazolam (1.5 nM) and GABA (5 μM) at the 
α1β2γ2L and α1β2γ2S GABAA receptors. MDZ: midazolam, Sevo: sevoflurane. The data is expressed as means ± SEMs (6 cells for γ2L and 4 cells 
for γ2S were used). (B) Sevoflurane (2.0%) enhancement of the currents evoked by the co-application of midazolam (15 nM) and GABA (5 μM) 
at the α1β2γ2L and α1β2γ2S GABAA receptors. MDZ: midazolam, Sevo: sevoflurane. The data is expressed as means ± SEMs (6 cells for γ2L and 3 
cells for γ2S were used). *P value < 0.05, when compared with γL-form.
Fig. 11. Sevoflurane (4.0%) enhancement of the currents evoked by 
the co-application of midazolam (300 nM) and GABA (5 μM) at the 
α1β2γ2L and α1β2γ2S GABAA receptors. MDZ: midazolam, Sevo: 
sevoflurane. The data is expressed as means ± SEM (4 cells for γ2L 
and 4cells for γ2S were used).
enabled midazolam to become the most popular sedative for 
anesthesia. Yet the suppression of respiration and cognitive 
function has limited its use [21]. 
    The long­term maintenance of a whole cell patch clamp 
after midazolam pretreatment and before the application of 
sevoflurane application, as in clinical practice, was difficult, 
so that we applied both drugs to the cells at the same time. 
Therefore, we cannot exclude the possibility of molecular and 
pharmacological changes of the GABAA receptors during the 
pretreatment with midazolam when interpreting our results. 
    Both midazolam and sevoflurane activate GABAA receptors, 
that is, they augment the binding of GABA to the receptor 
and facilitate the opening of chloride channels [10,22,23]. 
The γ subunit is essential for the binding of benzodiazepine 
to the GABAA receptor. Benzodiazepine does not increase the 
membrane potentials activated by GABA in the GABAA receptor 
without the γ subunit [16,24]. The γ2 subunit plays an important 
role in postsynaptic anchoring and intracellular incorporation of 
the GABAA receptor [25]. The RNA of the γ2 subunit of the GABAA 
receptor is spliced alternatively into the long (γ2L) form and 
the short (γ2S) form, and each has different pharmacological 
properties. A mutation of the γ2 subunit of the GABAA receptor 
is closely associated with familial idiopathic epilepsy [26]. A 
marked reduction of the γ2S subunit and the associated relative 
increase of the γ2L subunit in the prefrontal cortex results in 
functionally less active GABAA receptors and this has severe 
consequence for the cortical integrative function, and it leads 
to schizophrenia [27]. In contrast, others have reported that 
the anxiety and sensitivity to benzodiazepine were higher in 
knockout mice that lacked the long splice than that in the control 
group [28]. 
    There is a phosphorylation site in the γ2L subunit. 
Phosphorylation plays an important role in the control of 
ligand­gated ion channels. Phosphorylation by PKC decreases 
the inward currents activated by GABA and then this inhibits 
GABAA receptor function [4]. Both γ2L and γ2S have the same 
phosphorylation site at Ser327, but the γ2L subunit has an 
additional phosphorylation site at Ser343 in an alternative 
splicing area [29]. PKC decreases the activity of the GABAA 
receptor at both sites, Ser327 and Ser343, by phosphorylation, 
yet the suppression of the receptor is greater at Ser343 [30]. 
This is because the alternative splicing makes conformational 
changes in the intracellular loop, where Ser343 exists, between 
the 3rd and 4th transmembrane domains. 
    The difference in the alternative splicing and the additive 117 www.ekja.org
Korean J Anesthesiol Eom, et al.
effects of midazolam and sevoflurane in the γ2S form and γ2L 
form in our study show the possibility of the individual diversity 
in the responses to both drugs. 
    While recovery is occurring from sevoflurane anesthesia, the 
concentration of sevoflurane gradually decreases to zero. We 
postulated that the emergence agitation occurs when gradual 
recovery from the inhibition of the central nervous system 
by the GABA pathway during this process is interrupted in 
certain subjects and this interruption can be overcome by the 
administration of benzodiazepine to partially re­activate the 
GABA pathway, with the agitation being suppressed. We could 
not reveal that the γ2L dominant property of children was closely 
related with emergence agitation after sevoflurane anesthesia 
because we failed to show the difference of the responses to only 
sevoflurane in both subtypes. Yet it is expected that pretreatment 
with midazolam additionally activates the GABAA receptors 
and this minimizes the emergence agitation from sevoflurane 
anesthesia in the relatively γ2S­dominant subjects, but not in the 
relatively γ2L­dominant subjects.
    In conclusion, the co­application of midazolam and 
sevoflurane showed different results according to the type of γ2 
subunit in the GABAA receptors. Further studies are needed in 
order to reveal the differences of drug responses for each subject 
according to the γ2L/γ2S ratio and to individualize the drug 
dosages when these drugs are used for anesthesia and sedation.
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